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Polymeric paramagnetic ion chelate molecules were synthesized and covalently linked 
to monoclonal antibodies. The labeled antibodies retained their antigen binding capacity 
in vitro while carrying up to an average of 50 paramagnetic ion chelates, enabling specifically 
bound antibody concentrations less than 2.0 pM to significantly reduce proton longitudinal 
relaxation times. o 1986 Academic press. Inc. 
The use of radiolabeled monoclonal antibodies (McAbs) as tissue-specific agents 
for external y camera imaging of tumors and other pathologies ( I )  has generated 
interest in the application of McAbs as tissue-specific camers of paramagnetic contrast 
for MRI. Attempts to adapt this technology to MRI have been limited by the low 
concentration of McAb that can be specifically localized in a region of pathologic 
tissue relative to the level of chelated paramagnetic ion needed to significantly reduce 
local proton relaxation times. A reduction in the longitudinal relaxation time ( T I )  of 
30% requires a free paramagnetic ion chelate concentration in the range of 50-100 
pM depending on the paramagnetic ion and chelate used (2). By conjugating the 
chelated paramagnetic ion directly to a macromolecule such that the ion’s molecular 
correlation time is increased, marked enhancement of the paramagnetic ion-mediated 
reduction in TI has been reported, reducing the minimal paramagnetic ion concen- 
tration approximately sixfold (3).  This enables McAbs bearing 3 to 4 chelates to reduce 
TI  by 30% at McAb concentrations as low as 3 pM. Tumor associated cell surface 
antigens are generally found at a density of lo5 to lo6 sites per cell (1) .  The concentration 
of antigenic sites in tissue where cell concentration is 5 X lo8 cells/ml would thus be 
expected to fall in the range of 0.1-2.0 pM. The tissue concentration of intravenously 
administered McAbs specifically localized in tumors in animal models used in im- 
munoscintigraphy experiments, however, is far lower, typically only a few nanomolar 
(4 ,  5).  Increasing the dose administered to the animals, using multivalent McAb cock- 
tails or regional administration such as via lymphatics (6), may allow for 
greater tissue concentrations, possibly as high as 0.0 1-0.10 pM. Certain tissue antigens 
which exist at very high density might allow for tissue concentrations of specifically 
localized McAb to substantially exceed 1 pM (7). Still, such cases are rare and with 
most antigen targets submicromolar concentrations of specifically localized McAb are 
likely to be the upper limit in viva McAbs bearing only a few chelates per antibody, 
while useful as carriers of radioisotopes for immunoscintigraphic imaging, are thus 
very limited in use as tissue-specific carriers of paramagnetic ions for MRI contrast. 
0740-3 194/86 $3.00 336 
Copynght 0 I986 by Academic Press, Inc 
All nghts of reproduction in any form reserved 
COMMUNICATIONS 337 
While paramagnetic ion chelates directly conjugated to a macromolecule gain proton 
relaxation enhancement (3), the direct conjugation of more than 3 or 4 chelates per 
antibody markedly diminishes the antibody’s immunoreactivity (8). To increase the 
number of paramagnetic ions carried by a McAb even further requires the use of a 
separate polymeric chelate molecule covalently bound to the antibody. In this com- 
munication we describe methods of derivatizing McAb with polymeric chelate mol- 
ecules. The modified antibodies retain their specific antigen binding capacity in vitro 
while carrying over 50 chelates of paramagnetic ions per antibody. 
Polymeric chelate molecules were synthesized using deferoxamine chelates of Fe3+ 
or DTPA (diethylenetriaminepentaacetic acid) chelates of Gd3+. Deferoxamine pos- 
sesses a free primary amine moiety which readily forms an amide bond with the acyl 
imidazole derivative of carboxylates. The free carboxylate groups of polyacrylic acid 
(average of 70 monomeric units) and polyglutamic acid (average of 90 units) were 
first converted to acyl imidazoles with carbonyldiimidazole in dry DMF and DMSO 
solvents, respectively, and then allowed to react with deferoxamine Fe3+ chelates in 
dry DMF. Subsequently, to provide free thiol functionality to the polymeric chelates, 
2-mercaptoethylamine (molar stoichiometry 1.2: 1 per polymer) was allowed to react 
with remaining acyl imidazoles and then the preparations dialyzed exhaustively against 
phosphate buffered saline to remove uncoupled chelate. It could then be determined 
spectrophotometrically that, of the available carboxylates on the polyacrylic and 
polyglutamic polymer backbones, 30% were coupled to deferoxamine. 
Polymeric chelates using DTPA were synthesized by allowing the free primary amino 
groups of a polyamine such as polylysine to react with the cyclic anhydride of DTPA 
to form an amide linkage. DTPA dicyclic anhydride was allowed to react with polylysine 
(average 66 monomeric units) in an aqueous bicarbonate solvent. Following dialysis, 
chelation of Fe3+ allowed the spectrophotometric determination that 20% of the avail- 
able free amines were coupled to DTPA. To provide free thiol functionality, a few 
remaining free amines were allowed to react with SPDP (N-succinimidyl-3-(2-pyri- 
dyldithio) propionate). 
TABLE 1 
Polvmeric Paramagnetic Ion Chelate Molecules 
Relaxivity of 
Average molecular Average number of free paramagnetic paramagnetic 
Relaxivity of polymer-bound 
weighta chelates carried chelateb chelateb 




deferoxamine-Fe” 2 1,000 25 1.9 2.2 
deferoxamine-Fe3’ 30,000 21 1.9 2.1 
DTPA-Gd” 19,000 14 4.6 5.5 
Based on gel exclusion chromatography Kav. 
20 MHz at 25°C. 
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As expected, the polymeric chelate preparations all yielded a broad distribution of 
molecular weights. Sephacryl S-200 gel permeation chromatography was therefore 
used to isolate fractions which correspond to polymers containing 25-30 deferoxamine 
Fe3+ chelates or 14 DTPA Gd3+ chelates (Table 1). The polymeric chelate molecules 
were then coupled to purified McAb preparation by the heterobifunctional coupling 
agent SMCC (succinimidyl-4-(N-maleimidomethyl) cyclohexane- 1 -carboxylate) which 
forms an amide linkage with the antibody lysine [ amino residues and a thioether 
bond with the free thiol moiety of the polymeric chelate molecule. McAbs in phosphate 
buffered saline were first allowed to react with a molar excess of SMCC, the unreacted 
SMCC was removed by G75 Sephadex exclusion chromatography, and then the de- 
rivatized antibodies were added to a molar excess (8:l) of polymeric chelate. The 
unreacted polychelate could be readily removed by Sephacryl S-300 exclusion chro- 
matography and the polymeric chelate coupled McAbs separated from free McAbs 
by DEAE ion exchange chromatography. The number of chelates bound per McAb 
was determined by spectophotometry and Lowry protein assay (deferoxamine-Fe3+ 
polychelates) or by chelation of radionuclide and Lowry protein assay (DTPA poly- 
chelate). SDS-polyacrylamide electrophoresis under reducing conditions of the prep- 
arations demonstrated reduced migration of primarily the heavy chain band corre- 
sponding to an increase of molecular weight in the range of 20,000 to 30,000. 
TABLE 2 
Immunoreactivity and Relaxivity of Paramagnetic Ion Chelate-Labeled Monoclonal Antibodies (McAbs) 
Immuno- 
reactivity Relaxivity per 
Chelates of labeled paramagnetic ion Relaxivity 
per McAb chelate per McAb 
McAb ("/.I (SKI  mMP) (s-1 mM-l ) 
Polyacrylic deferoxamine-Fe3+ 
coupled to McAb 
5: 1 SMCC:McAb" 
15:l SMCCMcAb 
Polyglutamic deferoxamine-Fe3' 
coupled to McAb 
5: 1 SMCC:McAb 
15: 1 SMCCMcAb 
Polylysine DTPA-Gd" 
coupled to McAb 
5: 1 SMCC:McAb 
15: 1 SMCC:McAb 
DTPA-Gd'+ directly 
coupled to McAb 
20: 1 CDTPA:MCAB~ 
100: 1 cDTPA:McAb 





































McAb at 3 mg/ml in phosphate buffer, pH 7.2, allowed to react with SMCC for 30 min at 23°C. 
McAb at 1 mg/ml in 0. I M bicarbonate buffer, pH 8.2, allowed to react with dicyclic anhydride DTPA 
for 1 h at 23°C. 
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To determine the fraction of immunoreactive conjugated antibody, McAb polymeric 
chelate conjugates were labeled with ”Fe and incubated with appropriate target cells 
under conditions of antigen excess. Parallel experiments were performed using McAbs 
labeled directly with DTPA by the dicyclic anhydride method (8). Immunoreactive 
fractions of the polymeric chelate conjugated McAbs comparable to that obtained 
with DTPA-labeled McAbs (2-3 chelates per McAb) are observed when SMCC:McAb 
stoichiometry is low (5: 1) and consequently the number of chelates carried per McAb 
fairly low. Higher SMCC loading and consequently more than one polychelate per 
McAb yielded expected increases in chelates carried per McAb at the expense of im- 
munoreactivity (Table 2). 
The relaxivity of the paramagnetic ion chelates is not changed significantly when 
the chelates are coupled to the polymeric supports or when the polymeric supports 
are in turn conjugated to the McAbs (Tables 1 and 2), suggesting the chelates enjoy 
a significant degree of rotational freedom when linked to the polymer backbones. 
When the polymeric paramagnetic ion chelate conjugated McAbs are allowed to spe- 
cifically saturate the target surface antigens of cells in suspension ( 5  X lo6 cells/ml), 
the cells washed three times and then brought to packing density (7.5 X lo5 cells/pl), 
the decrease in T,  of the packed cells is consistent with the antibody concentration 
(measured using radiolabeled McAbs) and the average number of chelates carried per 
McAb (Table 3). 
Thus, by use of polymeric paramagnetic ion chelates, it becomes possible to sig- 
nificantly reduce T,  with McAb specifically bound to cell surface antigens in vitro. In 
these experiments the lower limit of McAb concentration required to significantly 
TABLE 3 
Effect of Antigen-Specific Bound Paramagnetically Labeled Monoclonal Antibody on the Longitudinal 
Relaxation Time of Packed Daudi Cells 
Concentration of specifically 
bound McAb in packed 
Chelates per cells“ Longitudinal relaxation timeb 
McAb (PW (ms) 
Polyacrylic deferoxamine-Fe” 52 
Cells preblocked with 
unlabeled antibody 
Polyglutamic deferoxamine-Fe’+ 58 
Cells preblocked with 
unlabeled antibody 
Polylysine DTPA-Gd” 30 




382 f 42 
652 f 53 
396 -t 36 
631 f 48 
380 f 62 
625 f 57 
unlabeled antibody 
Direct DTPA-Gd’+ 3.2 1.5 436 f 40 
664 f 58 Cells preblocked with 
unlabeled antibody 
a Determined in a parallel assay using radiolabeled antibody. 
20 MHz at 2 5 T ,  7.5 X lo5 cells/pl, 30 pl total volume. Values are means of triplicate experiments 
k standard deviation. 
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reduce TI  (- 30% reduction) appears to be roughly 1.5 pM. Further refinements such 
as polychelate molecules which are larger or have higher levels of chelate substitution 
and site-specific coupling of the polymeric chelate to the McAb could be used to 
improve the immunoreactivity of preparations that can significantly reduce TI  at 
submicromolar concentrations. If polymeric chelate molecules can be designed to 
increase the chelated ion’s effective correlation time such that proton relaxation en- 
hancement occurs ($, the required McAb concentration might be reduced to 0.2 pM 
or less. It may be possible to achieve such specifically bound antibody concentration 
in vivo in tissues containing high levels of available target antigens, but with tumor 
associated antigens even 0.2 pM would be extremely difficult to reach in most circum- 
stances. It should also be noted that typically only a few percent of the intravenously 
administered McAb localizes in the target tissue (4 ,  5 )  so that to reach a concentration 
of 0.2 pM in the target tissue comprising 0.5% body weight would require nearly 1 
mg of labeled antibody for a mouse, or over 1000 mg for a human subject; a substantial 
dose of a potentially immunogenic biologic. 
These numerical realities should be kept in mind with regard to assessing potential 
usefulness of McAbs as tissue-specific carriers of paramagnetic contrast for MRI. The 
low density of tumor associated antigens severely limits the practicality of detecting 
neoplasms with antibody-directed paramagnetic contrast. So, while practical appli- 
cation of McAb-directed paramagnetic contrast in MRI will probably require the use 
of polymeric chelate conjugates as a means of dramatically increasing the ability of 
each McAb to reduce local proton relaxation times, the detection of neoplasms in 
particular will require maximal refinements in this approach as well as further advances 
in the development of tumor associated antigen-specific McAbs. 
Finally, the most critical aspect of developing this technology will be the in vivo 
behavior of polymeric chelate conjugated McAbs. The influence of size, overall con- 
formation, charge distribution, and other properties of different polymeric chelate 
formulations on the biodistribution, degree of extracirculatory penetrance, antigenicity 
and metabolic fate of its McAb conjugates will determine the limits of this approach, 
and thus, we believe, the practicality of using McAbs to specifically localize paramag- 
netic contrast agents for MRI. 
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